CLAIMS

1. Use of NUC-1031 (gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate) in the manufacture of a medicament for cancer stem cell targeting adjuvant or neo-adjuvant treatment of cancer.

2. The use according to claim 1 wherein the medicament is to be used for the treatment of relapsed cancer in a human patient.

3. The use according to claim 1 wherein the medicament is to be used for the treatment of refractory cancer in a human patient.

4. The use according to any preceding claim, wherein targeting of cancer stem cells causes their death.

5. The use according to any preceding claim wherein the medicament is to be used for the treatment of cancer by reducing or preventing cancer development.

6. The use according to any preceding claim wherein the medicament is to be used for the treatment of cancer by reducing or preventing cancer progression.

7. The use according to any preceding claim wherein the medicament is to be used for the treatment of cancer by reducing or preventing cancer recurrence.

8. The use according to any preceding claim wherein the medicament is to be used for the treatment of cancer by reducing or preventing cancer propagation.

9. The use according to any preceding claim wherein the treatment of cancer is for a cancer selected from the group consisting of: leukaemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid carcinoma, skin cancer (including melanoma), oral squamous cell carcinoma, bladder cancer, Leydig cell tumour, biliary cancer, such as cholangiocarcinoma or bile duct cancer, pancreatic cancer, colon cancer, colorectal cancer, osteosarcoma and gynaecological cancers, including ovarian cancer, endometrial cancer, fallopian tube cancer, uterine cancer and cervical cancer.

10. The use according to claim 9, wherein the leukaemia is selected from the group consisting of acute lymphoblastic leukaemia, acute myelogenous leukaemia (also known as acute myeloid leukaemia or acute non-lymphocytic leukaemia), acute promyelocytic leukaemia, acute lymphocytic leukaemia, chronic myelogenous leukaemia (also known as chronic myeloid

leukaemia, chronic myelocytic leukaemia or chronic granulocytic leukaemia), chronic lymphocytic leukaemia, monoblastic leukaemia and hairy cell leukaemia.

11. The use according to claim 9, wherein the cancer is acute lymphoblastic leukaemia.

12. The use according to claim 9, wherein the lymphoma is selected from the group consisting of: Hodgkin's lymphoma; non-Hodgkin lymphoma; Burkitt's lymphoma; and small lymphocytic lymphoma.

13. The use according to any preceding claim, wherein the medicament is to be administered at a weekly dose of between 250 mg/m^2 and 1000 mg/m^2.

14. The use according to claim 13, wherein the medicament is to be administered at a weekly dose of between 375 mg/m^2 and 900 mg/m^2.

15. The use according to any claim 13, wherein the medicament is to be administered at a weekly dose of between 500 mg/m^2 and 825 mg/m^2.

16. The use according to any one of claims 1 to 12, wherein the medicament is to be administered at a dose of between approximately 500 mg/m^2 and 1000 mg/m^2 per week in at least one initial cycle of treatment, and then to be administered at a lower weekly dose in at least one further cycle of treatment.